Allurion Shares Jump on Weight-Loss Study Results

Dow Jones

2025/05/28

By Dean Seal

Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage.

The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday.

The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%.

The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 27, 2025 17:44 ET (21:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538973204"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538973204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538973204?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538973204","market":"us","top_or_hot":-1,"title":"Allurion Shares Jump on Weight-Loss Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n</p>\n<p>\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n</p>\n<p>\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n</p>\n<p>\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Shares Jump on Weight-Loss Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Shares Jump on Weight-Loss Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-28 05:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n</p>\n<p>\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n</p>\n<p>\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n</p>\n<p>\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消费者服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538973204","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538973204","pubTimestamp":1748382240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage.The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday.The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%.The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","ALUR":"Allurion Technologies Inc."},"translate_title":"Allurion股价因减肥研究结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9},"content_text":"By Dean Seal \n\n\n  Shares of Allurion Technologies climbed after patients treated with its weight-loss program in a clinical study maintained higher muscle mass and had a bigger decrease in fat percentage. \n\n\n  The stock jumped 20% to $3.36 in aftermarket trading. Shares were changing hands at $40.75 this time a year earlier and were down 74% year-to-date when the market closed Tuesday. \n\n\n  The developer of obesity treatments said after the closing bell on Tuesday that 1,962 patients treated in France with the Allurion Program, which uses swallowable gastric balloons, showed muscle mass as a percentage of body weight rising on average by 6.6%, while fat mass decreased on average by 11%. \n\n\n  The company also noted that shipments to France have resumed after its products were pulled last year over safety concerns. The company was cleared to start selling the products again earlier this year. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 17:44 ET (21:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}